Silver Book Fact

Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.

Ettinger, Bruce et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women with Osteoporosis Treated with Raloxifene: Results from a 3-year randomized clinical trial. JAMA. 1999; 282(7): 637-45. http://jama.ama-assn.org/cgi/content/abstract/282/7/637?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=Reduction+of+Vertebral+Fracture+Risk+in+Postmenopausal+Women+with+Osteoporosis+Treated+with+Raloxifene&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT

Reference

Title
Reduction of Vertebral Fracture Risk in Postmenopausal Women with Osteoporosis Treated with Raloxifene: Results from a 3-year randomized clinical trial
Publication
JAMA
Publication Date
1999
Authors
Ettinger, Bruce et al.
Volume & Issue
Volume 282, Issue 7
Pages
637-45
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Clinical studies in nutrition and physical activity interventions have proven that fractures can be prevented, even in older individuals, and that they do not need to be a natural consequence…  
  • Genetics can account for up to 75% of bone mineral density (BMD). Researchers have identified a gene that strongly influences peak bone mass in mice. The gene was not previously…  
  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.  
  • Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.